OUR EXPERT NETWORK

• Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future Directions

  This last article of the author's series on AOCs reveals regulatory perspective, analytical opportunities, the emergence of molecular quality by design, and the CMC challenges to address with future work.

• Antibody–Oligonucleotide Conjugates, Part 3: Analytical Control

  Let's delve into analytical control strategy, OAR/DAR measurement, bioanalytical characterization, stability and formulation, and more.

• Antibody–Oligonucleotide Conjugates, Part 2: Manufacturing

  Let's delve into manufacturing strategy, conjugation chemistry, process development and scale-up, and purification: the central manufacturing challenge.

• CDMOs Co-Author The RNA Ecosystem

  Praise to the RNA innovators, and our innovative service providers. You’ve brought us a long way. Still, that progress hasn’t necessarily made it easier to strategize the outsourcing of specific RNA-based projects. We’ve expanded development programs therapeutically and dialed up nuanced production requirements. So the current question is what will the RNA outsourcing ecosystem look like a few years from now? Here’s some expert analysis.

• Antibody–Oligonucleotide Conjugates, Part 1: Approaching Your AOC Development Plan

  The emergence of antibody–oligonucleotide conjugates (AOCs) addresses delivery issues with huge potential. Let's look at how to approach your development plan with molecular architecture, defining the target product profile, and CQAs.